Feature|Articles|April 17, 2024
- Pharmaceutical Executive: April 2024
- Volume 44
- Issue 4
Pharmaceutical Executive: April 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
Power in Partneringover 1 year ago
The IRA Impact: Navigating Its Evolving Complexitiesover 1 year ago
Fighting for Innovationover 1 year ago
Say Hello to Flexible: Reimagining the Patient Journeyalmost 2 years ago
Aspiring for the C-Suite? Consider Being a Chief of Staffalmost 2 years ago
Latent Benefit of Access Restrictions for Rare Conditionsalmost 2 years ago
The Biotech Rally has Legs—But Rising Tide Isn’t Lifting All Boatsalmost 2 years ago
The Pharmaceutical Playbook for Asia’s Private Marketalmost 2 years ago
Operating Models for Successful DOL EngagementNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
3
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
4
How is Re-Vana Using its Sustained-Delivery Hydrogel Technology to Position Itself as a Long-Term Partner at the 2026 J.P. Morgan Healthcare Conference?
5